https://biotechmorning.com/news/alumis-250m-ipo-back-to-back-raises Biotech Morning en 2026-06-28T14:24:47.990Z Alumis Just Raised $250M Going Public. Three Months Ago, It Raised $259M. https://biotechmorning.com/news/immunovant-39m-batoclimab-termination Biotech Morning en 2026-06-28T14:23:56.299Z Immunovant Just Paid $39M to Walk Away From a Drug That Didn't Work https://biotechmorning.com/news/cipepofol-china-anesthetic-fda-approval Biotech Morning en 2026-06-28T14:23:13.681Z The Anesthetic That Crossed the Pacific and Made FDA History https://biotechmorning.com/news/incyte-120m-genesis-ai-drug-discovery-bet Biotech Morning en 2026-06-28T14:22:14.132Z Incyte Just Bet $120M That AI Can Build Its Next Drug Pipeline https://biotechmorning.com/news/liminatus-innocsai-320m-all-stock-deal Biotech Morning en 2026-06-28T14:21:19.777Z A Biotech Worth $5 Million Just Bought a Company for $320 Million https://biotechmorning.com/news/annexon-huntington-patient-dropouts-stock-crash Biotech Morning en 2026-06-28T14:20:26.242Z Five Patients Quit and Annexon Lost a Third of Its Value https://biotechmorning.com/news/lilly-202m-engage-dna-delivery-acquisition Biotech Morning en 2026-06-28T14:19:30.200Z Lilly Just Paid $202M for a Company With Zero Drugs https://biotechmorning.com/news/biogen-apellis-pipeline-gutted Biotech Morning en 2026-06-28T14:18:35.407Z Biogen Spent $5.6B on Apellis. Then It Torched the Science. https://biotechmorning.com/news/infex-therapeutics-resp-x-phase-2a-ncfb-insmed Biotech Morning en 2026-06-28T14:17:34.037Z The Tiny UK Biotech Trying to Out-Insmed Insmed https://biotechmorning.com/news/parabilis-670-million-ipo-no-phase-3 Biotech Morning en 2026-06-27T14:23:04.037Z The Biotech That Raised $670 Million Before It Even Has a Phase 3 Trial https://biotechmorning.com/news/needle-free-epipen-alternative-insurance-wont-cover Biotech Morning en 2026-06-27T14:22:09.501Z A Needle-Free EpiPen Alternative Exists. Your Insurance Probably Won't Cover It. https://biotechmorning.com/news/bio-2026-china-biosecure-ai-drug-discovery Biotech Morning en 2026-06-27T14:21:11.885Z Biotech's Biggest Week Had Three Words on Everyone's Lips https://biotechmorning.com/news/ibio-ai-obesity-drug-clinical-trial Biotech Morning en 2026-06-27T14:20:16.155Z A Plant Factory Just Sent an AI-Designed Obesity Drug to the Clinic https://biotechmorning.com/news/first-muscle-gain-fshd-epicrispr-epi-321 Biotech Morning en 2026-06-27T14:19:23.888Z The First Drug to Ever Build Muscle in This Dystrophy Just Showed Up https://biotechmorning.com/news/viridian-lumvoa-fda-approval-thyroid-eye-disease Biotech Morning en 2026-06-27T14:18:33.759Z The Eye Drug That Just Beat Its Own Deadline https://biotechmorning.com/news/boehringer-immunai-t-cell-target-discovery Biotech Morning en 2026-06-27T14:17:41.284Z Boehringer's $15M Bet That the Next PD-1 Is Hiding in Your T Cells https://biotechmorning.com/news/pharma-ma-boom-2026-shopping-spree Biotech Morning en 2026-06-27T14:16:47.388Z Big Pharma Is on a $123 Billion Shopping Spree (and It's Only June) https://biotechmorning.com/news/lantheus-lnth-2501-crl-manufacturing-delay Biotech Morning en 2026-06-27T14:15:52.356Z Lantheus Had the Data. The Factory Broke the Dream. https://biotechmorning.com/news/biogen-apellis-acquisition-rd-cuts Biotech Morning en 2026-06-27T14:14:58.389Z Biogen Spent $5.6 Billion on Apellis. Then It Gutted the Lab.